MC Services AG

Just one month to go until Biotech Showcase™ 2025 – a premier investor conference committed to creating a platform for private and micro-mid-cap biotechnology companies –, happening in San Francisco January 13-15, 2025, and virtually January 21-22, 2025! We are proud to be a Media Partner for this important event, co-produced by EBD Group and Demy-Colton, that brings together innovators, investors, and industry leaders to shape the future of healthcare. Key Highlights of Biotech Showcase 2025: 🔬 Cutting-edge presentations from biotech companies, showcasing their latest innovations and advancements. 💡 Specialized tracks, including the TechBio Showcase (AI-driven healthcare, digital therapeutics) and the Seed Showcase (early-stage innovation). 🤝 One-on-one meetings facilitated by partneringONE™ – connect with global leaders driving the life sciences sector forward. 🎤 Plenary sessions and workshops, featuring expert insights on market trends, policy updates, and the future of healthcare. Join us! This is your chance to be at the center of the action – connect, collaborate, and explore new opportunities in biotech innovation. Visit the Biotech Showcase website to learn more and register today https://lnkd.in/g6tnDj5 #BiotechShowcase #LifeSciences #Innovation #MediaSupport #Biotech #Healthcare

We are celebrating ten amazing years of Julia von Hummel's dedication at MC Services AG! 🎉   Julia has a background in biology and a passion for transforming complex scientific topics into compelling stories. Alongside her expertise in corporate communications and writing impactful articles, her active role in Wissenswerte, the German-speaking forum for science journalism, reflects her commitment to advancing scientific communications and fostering meaningful dialogue. Her strategic thinking, steadfast support, especially for younger team members, and ability to tackle challenges with calm determination have made her an invaluable part of our team.   Thank you, Julia, for your dedication, expertise and sharp sense of humor. Here's to many more years together! 🥂

We had an incredible few days at #EKF24! We proudly hosted the press lounge, moderated the lifescience track and supported valuable connections throughout the event. A big thank you to all attendees, partners, and presenters for making EKF 2024 a success. We look forward to continuing these collaborations in investor and media relations. It is our mission to spread the word about the innovative life science sector. Visit us on YouTube for industry insights from EKF24: https://bit.ly/3APBptq #EKF2024 #Biotech #CorporateFinance #Networking #LifeSciences Deutsche Börse Cash Market

🌍 "The biosimilar market is on, it's growing, it's accelerating, and there's clearly the demand. It will continue to grow in all major regions: US, Europe, MENA, and therefore we have a very strong basis from which we can work." – Enno Spillner, CFO, Formycon AG. Formycon AG is a leading developer of high-quality biosimilars, offering treatments in ophthalmology, immunology, and immuno-oncology. The company has recently achieved milestones such as approvals in the US and Europe and the initiation of new clinical programs. Watch the full interview with Enno Spillner to learn more about their recent successes and what's next for Formycon at EKF 2024. 🎥 For more interviews from EKF24 visit: https://bit.ly/3V08PMJ #Biosimilars #TeamFormycon #FYB #IR #EKF24 #DeutschesEigenkapitalforum

At #EKF24, we spoke with Heidelberg Pharma AG's CFO Walter Miller about their progress with ADCs that combine antibody specificity with potent toxins to target cancer. Their lead candidate in multiple myeloma is showing convincing toxicity and early efficacy data with exciting milestones ahead, including an upcoming Phase II/IIa trial and new developments in non-Hodgkin’s lymphoma. 📺 Click on the link for more insights from the Deutsches Eigenkapitalforum 2024 (German Equity Forum): https://bit.ly/3OeCihZ   #ADC #ATAC #MultipleMyeloma #Amanitin #biotech #pharma #DeutschesEigenkapitalforum

"We are currently in the iterative process with the FDA and expect to finalize it in Q1 2025, launching our product commercially in the US," shared Loïc Moreau, President International at Nyxoah. The Belgian medtech company is developing innovative neurostimulation treatments for Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with serious comorbidities like cardiovascular diseases or depression. With its CE-marked Genio® system, Nyxoah aims to improve lives through restful nights.🌙✨ Watch the video below to find out more about how Nyxoah is preparing to enter the US market and why #EKF24 is the perfect platform to share these developments.    See more interviews from EKF24 here: https://bit.ly/3UYWF6u  📹   #Medtech #sleepapnea #neurostimulation #DeutschesEigenkapitalforum

🎙️ "2025 is exciting because really it's, for Carbios, the first generation of revenues." – Emmanuel LADENT, CEO of CARBIOS. At #EKF2024, Emmanuel  shared how Carbios is transforming the life cycle of plastics and PET textiles through groundbreaking enzyme-based depolymerization solutions. The Company is making strides toward commercialization with an industrial plant under construction in France and licensing agreements globally, marking a major step in achieving full circularity for plastic waste. Watch the full interview to learn more about Carbios' journey and vision for the future: https://bit.ly/40SQnJu #PlasticPollution #CircularEconomy #Sustainability #Emballage #Compostabilité #EKF24 #DeutschesEigenkapitalforum

📢 “The companies love the EKF, they mark it in their calendars at the beginning of the year, already asking for next year, “ says Jacqueline Jankang, Head of Issuer Services, Deutsche Börse Jacqueline Jankang shared how the #DeutschesEigenkapitalforum (EKF) has become one of the leading capital market conferences worldwide, attracting 2,000 participants, 250 companies and over 1,000 investors. Stay tuned for even more exciting developments in 2025!   Visit our YouTube channel to learn about EKF's impact on the capital markets: https://bit.ly/3Ok6Rmk   #EKF24 #CapitalMarkets #DeutscheBoerse #InvestorConference #equity Deutsche Börse Cash Market

🚀 "We do not depend on a bio-premium to be profitable. This is very important to be competitive and to be able to penetrate this market." – Maxime Cordonnier, CFO of AFYREN. Afyren, a pioneer in green chemistry, is leveraging bio-based technologies to replace petrochemical ingredients. Their solutions are not only sustainable but also cost-competitive, with a focus on decarbonization in sectors like nutrition, fragrances, and technical fluids. 📹 Learn more about Afyren’s innovative industrial plant and ambitious plans at the Deutsches Eigenkapitalforum 2024. For more interviews from EKF24 visit: https://bit.ly/3Zaq3cG #Sustainability #CSR #SustainableInnovation #GreenChemistry #EKF24 #DeutschesEigenkapitalforum

"The real game changer is the next drug coming, that’s Evenamide: an innovative treatment for patients suffering from schizophrenia. If we look ahead to the next 6 months, the most exciting thing will be that we get a first partner on board and then the start of the one-year, double-blind, placebo-controlled landmark study in patients with treatment-resistant schizophrenia.” explains Stefan Weber, CEO of Newron Pharmaceuticals SpA at #EKF24 hosted by Deutsche Börse Cash Market .   Newron is focused on research and development of innovative CNS compounds. With its lead compound, the Company intends to change the treatment paradigm in #schizophrenia. 🧠   🎥For more insights from EKF visit our YouTube channel: https://bit.ly/3UXUOio   #Newron #Evenamide #Neuroscience #NovelTherapies #DeutschesEigenkapitalforum